<DOC>
	<DOCNO>NCT00527462</DOCNO>
	<brief_summary>The aim study test hypothesis allergic airway inflammation asthmatic patient enhance exposure ultrafine particle ( UFP ) . In order test control study , researcher combine control exposure carbon black model UFP well-established model segmental allergen challenge , allow researcher safely induce circumscript allergic inflammation lung mild asthmatic . The effect UFP allergic inflammation control inhalation clean air randomize , double-blind , crossover design .</brief_summary>
	<brief_title>Study Explore Effects Two Hour Inhalation Ultrafine Carbon Black Particles Airway Inflammation Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>Male female subject , age 1845 year . Women consider inclusion : Not pregnant , confirmed pregnancy test nursing . Not childbearing capacity ( i.e . physiologically incapable become pregnant , include female premenarchial postmenopausal , document proof hysterectomy tubal ligation , meet clinical criterion menopause amenorrheal 1 year prior screen visit ) . Of childbearing capacity use highly effective method contraception entire study ( vasectomised partner , sexual abstinence [ lifestyle female complete abstinence intercourse two week prior first dose study medication least 72 hour treatment ] , implant , injectables , combine oral contraceptive , hormonal intrauterine device [ IUDs ] ) . Physician diagnosis mild intermittent seasonal asthma Nonsmokers , exsmokers Forced expiratory volume 1 second ( FEV1 ) &gt; 80 % predict value Positive skin prick test grass mix within 12 month prior screen visit Able willing give write informed consent take part study Available complete study measurement Able restrain particle rich atmosphere ( e.g . passive cigarette smoke ) within 1 week exposure UFP clean air Infections respiratory tract within last month Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , tuberculosis , bronchiectasis cystic fibrosis ) . Pathological finding safety laboratory test Subjects clinically relevant infection know ongoing clinically relevant inflammatory process Suspected hypersensitivity ingredient medication involve bronchoscopy ( bronchodilator , sedatives local anaesthetic ) Specific immunotherapy ( SIT ) within two year prior study Administration oral , injectable , dermal corticosteroid accord 9.2 Neurological psychiatric disease history drug alcohol abuse would interfere subject 's proper completion protocol assignment Risk noncompliance study procedure Participation another clinical trial 30 day prior enrolment Suspected inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study . Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , language problem , uncooperative attitude , inability return followup visit , improbability completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Asthma GINA 1</keyword>
</DOC>